<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20161221031505N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-06-25</date_registration>
      <primary_sponsor>Tehran University of Medical Sciences</primary_sponsor>
      <public_title>Assessing the efficacy of different medications in decreasing complications of transureteral lithotripsy</public_title>
      <acronym></acronym>
      <scientific_title>Comparison the effect of single dose medication in decreasing urgent ureteroscopy complications, a double blind randomized clinical trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-07-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>400</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/63862</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Block randomization
In this section using the site 
(https://www.sealedenvelope.com/simple-randomiser/v1/lists)
randomization is done with quadruple blocks (equal to the number of groups). The list of each of four patients is entered in a block, respectively. The first and second-year urology assistants who are responsible for preparing the patient in the urology ward will give the necessary dose to the patient and record it and then the patient is transported to the operating room without knowing about the medicine received, Blinding description: The medication is prescribed and registered by the first-year assistant in the ward without mentioning its name to the patient and the stone crushing is done by the third-year assistant in the operating room without knowing the medication.</study_design>
      <phase>3</phase>
      <hc_freetext>Ureteral stone.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group number 1: 1 amp. Hyoscine 20 mg made by Exir company diluted in one liter normal saline is infused via vein catheter 1 hour before intervention. Intervention 2: Intervention group number 2: 1 amp. ketorolac 30 mg made by Exir company diluted in one liter normal saline is infused via vein catheter 1 hour before intervention. Intervention 3: Intervention group number 3: 2 caps. Tamsulosin made by Exir company is prescribed for the patient and tomorrow one liter normal saline is infused via vein catheter during one hour before surgery. Intervention 4: Control group or intervention 4: 1 liter normal saline is infused one hour before surgery.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All data will be provided to the Vice-Chancellor for Research of Tehran University of Medical Sciences as a dissertation

When:
6 months after the publication of the article

To whom:
Scientific institutes and researchers

Conditions:
To share experiences and increase citations

Where to obtain:
To the e-mail address of Dr. Hamed Akhvizadegan 
(h-akhavizadegan@tums.ac.ir)

How to obtain:
Up to one month after the email and review of the application and then obtaining the license of the Vice Chancellor for Research, information will be provided to the person.

Comments:
In addition, because the research is a dissertation, a copy of it is available to the public in the Central Library as well as in the library of Sina Hospital.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Hamed Akhavizadegan</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Hasan Abad square, Sina hospital</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1136746911</zip>
        <telephone>+98 21 6312 1538</telephone>
        <email>h-akhavizadegan@tums.ac.ir</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Hamed Akhavizadegan</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Sina hospital, Hasan abad square</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1136746911</zip>
        <telephone>+98 21 6312 1538</telephone>
        <email>h-akhavizadegan@tums.ac.ir</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Candidates of transureteral lithotripsy</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Renal dysfunction, Creatinine more than 1.5 mg/dl
Previous ureteral intervention
Having Double J or ureteral catheter
age higher than 65
Weight less than 50 kg
Contraindication or allergy to medications used in project
History of using medications before intervention
Patient does not want to participate in study</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>N 21</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group number 1: 1 amp. Hyoscine 20 mg made by Exir company diluted in one liter normal saline is infused via vein catheter 1 hour before intervention.</i_keyword>
      <i_keyword>Intervention group number 2: 1 amp. ketorolac 30 mg made by Exir company diluted in one liter normal saline is infused via vein catheter 1 hour before intervention.</i_keyword>
      <i_keyword>Intervention group number 3: 2 caps. Tamsulosin made by Exir company is prescribed for the patient and tomorrow one liter normal saline is infused via vein catheter during one hour before surgery.</i_keyword>
      <i_keyword>Control group or intervention 4: 1 liter normal saline is infused one hour before surgery.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Reducing damage to the bladder. Timepoint: During TUL. Method of measurement: Observing procedure.</prim_outcome>
      <prim_outcome>Reducing  damage to the ureteral entrance to the bladder. Timepoint: During TUL. Method of measurement: Observing procedure.</prim_outcome>
      <prim_outcome>Reducing  ureteral mucosa injury. Timepoint: During transurethral lithotripsy. Method of measurement: Observing the procedure.</prim_outcome>
      <prim_outcome>Reducing ureteral perforation. Timepoint: During transurethral lithotripsy. Method of measurement: Observing the procedure.</prim_outcome>
      <prim_outcome>Reducing  ureteral stone riching failure. Timepoint: During transurethral lithotripsy. Method of measurement: Observation the procedure.</prim_outcome>
      <prim_outcome>Reducing inability to enter the ureter. Timepoint: During transurethral lithotripsy. Method of measurement: Observation during procedure.</prim_outcome>
      <prim_outcome>Reducing  ureteral avulsion. Timepoint: During transurethral lithotripsy. Method of measurement: Observing during procedure.</prim_outcome>
      <prim_outcome>Reducing  the need for a narrower ureteroscope. Timepoint: During transurethral lithotripsy. Method of measurement: Observing during procedure.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tehran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-08-27</approval_date>
        <contact_name>Ethical committee of Tehran University of Medical Sciences</contact_name>
        <contact_address>Sina hospital, Hasn Abad square, Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
